Pharmaceutical - Respiratory and Pulmonary, Research

Filter

Popular Filters

1 to 25 of 89 results

GSK COPD survey shows many sufferers underestimate the severity of their condition

GSK COPD survey shows many sufferers underestimate the severity of their condition

12-11-2014

UK pharma major GlaxoSmithKline has conducted a global survey of people living with chronic obstructive…

GlobalGSKPharmaceuticalResearchRespiratory and PulmonaryUnited States

Positive results for Sanofi/Regeneron’s dupilumab in asthma

Positive results for Sanofi/Regeneron’s dupilumab in asthma

11-11-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have released positive results from…

dupilumabFrancePharmaceuticalRegeneron PharmaceuticalsResearchRespiratory and PulmonarySanofi

Vectura gets VR315 US development milestone

07-11-2014

UK inhaled therapies developer Vectura Group says that it has triggered a further milestone associated…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVectura GroupVR315

Janssen collaborating International Union Against Tuberculosis and Lung Disease on Sirturo study

Janssen collaborating International Union Against Tuberculosis and Lung Disease on Sirturo study

06-11-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary is to collaborate with the International…

bedaquilineJanssenPharmaceuticalResearchRespiratory and PulmonarySirturo

Almirall transfers rights to respiratory business to AstraZeneca

Almirall transfers rights to respiratory business to AstraZeneca

03-11-2014

Spanish pharma company Almirall has transferred the rights to its respiratory franchise to Anglo-Swedish…

AlmirallAstraZenecaEkliraPharmaceuticalResearchRespiratory and PulmonarySpain

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

10-09-2014

A pre-specified subgroup analysis from the two replicate Phase III INPULSI trials, presented today at…

Boehringer IngelheimnintedanibPharmaceuticalResearchRespiratory and Pulmonary

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

09-09-2014

German family-owned drug major Boehringer Ingelheim has reported Phase III trial results showing that…

AsthmaBoehringer IngelheimGermanyMajorPharmaceuticalPulmonologyResearchRespiratory and Pulmonarytiotropium

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

08-09-2014

UK inhalation drug delivery specialist Skyepharma today announced that data from a randomized, multicenter,…

FlutiformGermanyMundipharmaPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySkyepharmaUK

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

02-09-2014

Japanese drugmaker Torii Pharmaceutical has begun a Phase II/III development program with Denmark-based…

ALK AbelloAllergologyImmunologyJapanMedicinePharmaceuticalResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug

GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug

16-07-2014

UK pharma major GlaxoSmithKline and its US partner Theravance have started a global Phase III study,…

Breo ElliptaChronic obstructive pulmonary diseaseCOPDGlaxoSmithKlinePharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryRespiratory therapyTheravanceUKUSA

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Stallergenes publishes review of grass pollen tablet confirming efficacy

Stallergenes publishes review of grass pollen tablet confirming efficacy

24-06-2014

French allergen specialist Stallergenes has released comprehensive new data on the 5-grass pollen immunotherapy…

FrancePharmaceuticalResearchRespiratory and PulmonaryStallergenes

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

23-06-2014

UK-based biotechnology company Verona Pharma says that the Phase IIa clinical trial to evaluate the efficacy…

PharmaceuticalResearchRespiratory and PulmonaryUKVerona Pharma

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

16-06-2014

Denmark-based allergy specialist ALK Abello partner for Japan, Torii Pharmaceutical, has completed its…

ALK AbelloJapanPharmaceuticalRegulationResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

10-06-2014

Danish allergy specialist ALK-Abello has presented positive key trial results on its new sublingual allergy…

Alk-AbelloPharmaceuticalResearchRespiratory and PulmonarySLIT-tablet

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

20-05-2014

UK pharma major GlaxoSmithKline has released data showing the safety and efficacy of the addition of…

AdvairGlaxoSmithKlineHealth Medical PharmaHealth Medical PharmaIncruse ElliptaMedicinePharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapyUK

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

1 to 25 of 89 results

Back to top